Fig. 1From: Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trialLSM change from baseline in mean MMD in (A) failed-yes/no and (B) concomitant preventive-yes/no subgroups. CI confidence interval, LSM least squares mean, MMD monthly migraine daysBack to article page